Akeso (HKG:9926) obtained approval for a supplementary new drug application for ivonescimab to treat non-small cell lung cancer from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.
The approval is for the indication of use of the drug as a monotherapy for the first-line treatment of PD-L1-positive (TPS 1%) non-small cell lung cancer patients.
This indication marks the second major approval for ivonescimab, according to the drug company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。